BU 224 hydrochloride |
| Catalog No.GC15700 |
Antagonist of I2 Imidazoline receptor,potent and selective
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 205437-64-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
BU 224 hydrochloride is a selective ligand of the imidazoline I2 receptor with Ki value of 2.1 nM [1].
Imidazoline receptor is the primary receptor for clonidine and other imidazolines. Imidazoline I2 receptor is an allosteric binding site of monoamine oxidase and plays a critical role in neuroprotection and pain modulation.
BU 224 hydrochloride is a selective ligand of the imidazoline I2 receptor. In the rat forced swim test (FST), BU224 significantly inhibited immobility and increased mild swimming. Also, BU224 increased adrenocorticotrophic hormone (ACTH) response to FST and 5-hydroxytryptamine (5-HT) levels in frontal cortex and reduced 5-HT turnover in the hypothalamus and frontal cortex. These results showed the antidepressant-like activity of BU224 [2]. In rats with unilateral lesion of the nigrostriatal tract, BU224 (14 mg/kg) significantly increased ipsiversive rotations [3]. In rats with warm water tail withdrawal procedure, BU224 inhibited the enhancement of morphine and tramadol antinociception induced by 2-BFI and agmatine [4].
References:
[1]. Hudson AL, Gough R, Tyacke R, et al. Novel selective compounds for the investigation of imidazoline receptors. Ann N Y Acad Sci, 1999, 881: 81-91.
[2]. Finn DP, Martí O, Harbuz MS, et al. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl), 2003, 167(2): 195-202.
[3]. Macinnes N, Duty S. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol, 2004, 143(8): 952-959.
[4]. Thorn DA, Zhang Y, Peng BW, et al. Effects of imidazoline I₂ receptor ligands on morphine- and tramadol-induced antinociception in rats. Eur J Pharmacol, 2011, 670(2-3): 435-440.
| Cas No. | 205437-64-5 | SDF | |
| Chemical Name | 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline hydrochloride | ||
| Canonical SMILES | C12=CC=CC=C1N=C(C3=NCCN3)C=C2.Cl | ||
| Formula | C12H11N3.HCl | M.Wt | 233.7 |
| Solubility | <2.34mg/ml in DMSO | Storage | Desiccate at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.279 mL | 21.395 mL | 42.7899 mL |
| 5 mM | 0.8558 mL | 4.279 mL | 8.558 mL |
| 10 mM | 0.4279 mL | 2.1395 mL | 4.279 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *